ABL1 and leukemia: Analysis of CRT signal on the surface of treated leukemia cells shows that doxorubicin, but not imatinib, a BCR-ABL inhibitor which is not known to induce ICD, induces CRT surface exposure (Supplementary Fig. 2b, d).